IN2014DN09261A - - Google Patents
Info
- Publication number
- IN2014DN09261A IN2014DN09261A IN9261DEN2014A IN2014DN09261A IN 2014DN09261 A IN2014DN09261 A IN 2014DN09261A IN 9261DEN2014 A IN9261DEN2014 A IN 9261DEN2014A IN 2014DN09261 A IN2014DN09261 A IN 2014DN09261A
- Authority
- IN
- India
- Prior art keywords
- genomic locus
- target genomic
- compositions
- methods
- homologous recombination
- Prior art date
Links
- 230000006801 homologous recombination Effects 0.000 abstract 2
- 238000002744 homologous recombination Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 101710163270 Nuclease Proteins 0.000 abstract 1
- 230000005782 double-strand break Effects 0.000 abstract 1
- 210000003527 eukaryotic cell Anatomy 0.000 abstract 1
- 238000012239 gene modification Methods 0.000 abstract 1
- 230000005017 genetic modification Effects 0.000 abstract 1
- 235000013617 genetically modified food Nutrition 0.000 abstract 1
- 210000001236 prokaryotic cell Anatomy 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 230000005783 single-strand break Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261638267P | 2012-04-25 | 2012-04-25 | |
| PCT/US2013/038165 WO2013163394A1 (en) | 2012-04-25 | 2013-04-25 | Nuclease-mediated targeting with large targeting vectors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN09261A true IN2014DN09261A (de) | 2015-07-10 |
Family
ID=48289700
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN9261DEN2014 IN2014DN09261A (de) | 2012-04-25 | 2013-04-25 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9834786B2 (de) |
| EP (1) | EP2847335B1 (de) |
| JP (1) | JP6275120B2 (de) |
| KR (1) | KR101904508B1 (de) |
| CN (2) | CN104364380B (de) |
| AU (1) | AU2013251558B2 (de) |
| BR (1) | BR112014026294B1 (de) |
| CA (1) | CA2869016C (de) |
| CY (1) | CY1120572T1 (de) |
| DK (1) | DK2847335T3 (de) |
| ES (1) | ES2683071T3 (de) |
| IL (1) | IL234905B (de) |
| IN (1) | IN2014DN09261A (de) |
| MX (1) | MX362523B (de) |
| PL (1) | PL2847335T3 (de) |
| PT (1) | PT2847335T (de) |
| RU (1) | RU2645475C2 (de) |
| SG (2) | SG11201406547YA (de) |
| WO (1) | WO2013163394A1 (de) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2014DN09261A (de) | 2012-04-25 | 2015-07-10 | Regeneron Pharma | |
| SG10201809817UA (en) | 2012-05-25 | 2018-12-28 | Univ California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
| CA2977152C (en) | 2012-12-06 | 2019-04-09 | Sigma-Aldrich Co. Llc | Crispr-based genome modification and regulation |
| EP3561050B1 (de) | 2013-02-20 | 2021-12-08 | Regeneron Pharmaceuticals, Inc. | Genetische modifikation von ratten |
| SI2986729T1 (sl) | 2013-04-16 | 2019-02-28 | Regeneron Pharmaceuticals, Inc. | Ciljana sprememba genoma podgane |
| WO2015040402A1 (en) | 2013-09-18 | 2015-03-26 | Kymab Limited | Methods. cells & organisms |
| KR101566498B1 (ko) * | 2013-11-13 | 2015-11-06 | 건국대학교 산학협력단 | 인터루킨 2 수용체 감마 유전자 적중벡터, 그 벡터가 도입된 면역세포 결핍 형질전환 미니 복제돼지 생산과 그 제조방법 및 활용 |
| US10787684B2 (en) | 2013-11-19 | 2020-09-29 | President And Fellows Of Harvard College | Large gene excision and insertion |
| DK3080279T3 (en) | 2013-12-11 | 2018-11-05 | Regeneron Pharma | METHODS AND COMPOSITIONS FOR TARGETED MODIFICATION OF A GENOM |
| KR102170502B1 (ko) * | 2013-12-11 | 2020-10-28 | 리제너론 파마슈티칼스 인코포레이티드 | 게놈의 표적화된 변형을 위한 방법 및 조성물 |
| JP6688231B2 (ja) * | 2014-06-06 | 2020-04-28 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 標的遺伝子座を修飾するための方法及び組成物 |
| SG10201911411YA (en) * | 2014-06-26 | 2020-02-27 | Regeneron Pharma | Methods and compositions for targeted genetic modifications and methods of use |
| WO2016061374A1 (en) | 2014-10-15 | 2016-04-21 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for generating or maintaining pluripotent cells |
| KR102531016B1 (ko) | 2014-11-21 | 2023-05-10 | 리제너론 파마슈티칼스 인코포레이티드 | 쌍 형성된 가이드 rna를 사용하는 표적화된 유전자 변형을 위한 방법 및 조성물 |
| NZ732895A (en) | 2014-12-19 | 2022-05-27 | Regeneron Pharma | Methods and compositions for targeted genetic modification through single-step multiple targeting |
| BR112017019620A2 (pt) | 2015-03-16 | 2018-05-15 | Regeneron Pharmaceuticals, Inc. | ?roedor geneticamente modificado, célula ou tecido, métodos para produção de um roedor geneticamente modificado e de uma população de neurônios motores, métodos para seleção de um agente candidato para modular a disfunção neuronal motora e de um agente candidato para redução do estresse oxidativo em um neurônio motor, ácido nucleico, e, célula de roedor? |
| SG10201911257YA (en) * | 2015-05-29 | 2020-01-30 | Regeneron Pharma | Non-human animals having a disruption in a c9orf72 locus |
| US10781453B2 (en) | 2016-09-30 | 2020-09-22 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a hexanucleotide repeat expansion in a C9ORF72 locus |
| IL319209A (en) | 2017-06-27 | 2025-04-01 | Regeneron Pharma | Non-human animals containing a humanized ASGR1 locus |
| SG11201912236YA (en) | 2017-07-31 | 2020-01-30 | Regeneron Pharma | Crispr reporter non-human animals and uses thereof |
| WO2019028029A1 (en) | 2017-07-31 | 2019-02-07 | Regeneron Pharmaceuticals, Inc. | EVALUATION OF CRISPR / CAS INDUCED RECOMBINATION WITH IN VIVO EXOGENIC DONOR NUCLEIC ACID |
| CA3067872A1 (en) | 2017-07-31 | 2019-02-07 | Regeneron Pharmaceuticals, Inc. | Cas-transgenic mouse embryonic stem cells and mice and uses thereof |
| SG11202000771UA (en) | 2017-09-29 | 2020-04-29 | Regeneron Pharma | Non-human animals comprising a humanized ttr locus and methods of use |
| ES2911249T3 (es) | 2017-11-10 | 2022-05-18 | Regeneron Pharma | Animales no humanos que comprenden una mutación de slc30a8 y métodos de uso |
| JP7361031B2 (ja) | 2017-11-30 | 2023-10-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒト化ｔｒｋｂ遺伝子座を含む非ヒト動物 |
| CN111885915B (zh) | 2018-03-19 | 2023-04-28 | 瑞泽恩制药公司 | 使用crispr/cas系统对动物进行转录调制 |
| ES2974200T3 (es) | 2018-09-13 | 2024-06-26 | Regeneron Pharma | Rata nuligénica para el gen del factor H del complemento como modelo de glomerulopatía C3 |
| CN116064550A (zh) | 2018-12-20 | 2023-05-05 | 瑞泽恩制药公司 | 核酸酶介导的重复扩增 |
| ES2966625T3 (es) | 2019-04-04 | 2024-04-23 | Regeneron Pharma | Roedores que comprenden un locus del factor de coagulación 12 humanizado |
| AU2020286382B2 (en) | 2019-06-04 | 2026-03-26 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized TTR locus with a beta-slip mutation and methods of use |
| JP7698587B2 (ja) | 2019-06-07 | 2025-06-25 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒト化アルブミン遺伝子座を含む非ヒト動物 |
| RU2722933C1 (ru) * | 2019-06-11 | 2020-06-05 | Автономная некоммерческая образовательная организация высшего образования Сколковский институт науки и технологий | Средство разрезания днк на основе cas9 белка из бактерии demequina sediminicola |
| WO2021108363A1 (en) | 2019-11-25 | 2021-06-03 | Regeneron Pharmaceuticals, Inc. | Crispr/cas-mediated upregulation of humanized ttr allele |
| KR20220133248A (ko) | 2020-01-28 | 2022-10-04 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화 pnpla3 좌위를 포함하는 비-인간 동물 및 사용 방법 |
| EP4099821A1 (de) | 2020-02-07 | 2022-12-14 | Regeneron Pharmaceuticals, Inc. | <smallcaps/>? ? ?klkb1? ? ? ? nichtmenschliche tiere mit humanisiertem locus und verfahren zur verwendung |
| EP4125348A1 (de) | 2020-03-23 | 2023-02-08 | Regeneron Pharmaceuticals, Inc. | Nichtmenschliche tiere mit einem humanisierten ttr-locus mit einer v30m-mutation und verfahren zur verwendung |
| EP4171215A2 (de) | 2020-06-26 | 2023-05-03 | Regeneron Pharmaceuticals, Inc. | Nicht-humane tiere mit einem humanisierten ace2-locus |
| KR20230152124A (ko) | 2021-03-05 | 2023-11-02 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 생체내 dna 조립 및 분석 |
| KR20240107104A (ko) | 2021-11-04 | 2024-07-08 | 리제너론 파마슈티칼스 인코포레이티드 | 변형된 cacng1 유전자좌를 포함하는 비인간 동물 |
| CA3238939A1 (en) | 2021-12-08 | 2023-06-15 | Gaurang Patel | Mutant myocilin disease model and uses thereof |
| US20250049006A1 (en) | 2021-12-20 | 2025-02-13 | C/O Regeneron Pharmaceuticals, Inc. | Non-human animals comprising humanized ace2 and tmprss loci |
| US20250194571A1 (en) | 2022-02-07 | 2025-06-19 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for defining optimal treatment timeframes in lysosomal disease |
| CA3242729A1 (en) | 2022-02-11 | 2023-08-17 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for screening 4r tau targeting agents |
| JP2025527122A (ja) | 2022-07-29 | 2025-08-20 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 改変型トランスフェリン受容体座位を含む非ヒト動物 |
| JP2025525745A (ja) | 2022-08-05 | 2025-08-07 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｔｄｐ－４３の凝集耐性バリアント |
| WO2024073679A1 (en) | 2022-09-29 | 2024-04-04 | Regeneron Pharmaceuticals, Inc. | Correction of hepatosteatosis in humanized liver animals through restoration of il6/il6r/gp130 signaling in human hepatocytes |
| KR20250144399A (ko) | 2023-02-01 | 2025-10-10 | 리제너론 파마슈티칼스 인코포레이티드 | 변형된 klhdc7b 유전자좌를 포함하는 동물 |
| WO2024189098A1 (en) | 2023-03-13 | 2024-09-19 | Iomx Therapeutics Ag | Platform technology for the identification of modulators of immune effector cell function |
| WO2025122754A1 (en) | 2023-12-07 | 2025-06-12 | Regeneron Pharmaceuticals, Inc. | Gaa knockout non-human animals |
| WO2025250495A1 (en) | 2024-05-28 | 2025-12-04 | Regeneron Pharmaceuticals, Inc. | Acceleration of human hepatocyte engraftment in humanized liver animals by supplementing paracrine ligands or agonists that activate human liver regeneration signals |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5830729A (en) | 1996-04-18 | 1998-11-03 | Institut Pasteur | I Sce I-induced gene replacement and gene conversion in embryonic stem cells |
| US5830698A (en) * | 1997-03-14 | 1998-11-03 | Idec Pharmaceuticals Corporation | Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same |
| CN1175111C (zh) | 1997-03-14 | 2004-11-10 | 艾德药品公司 | 将基因整合至哺乳动物细胞特定位点的方法及所用载体 |
| WO2000039316A1 (en) | 1998-12-31 | 2000-07-06 | The J. David Gladstone Institutes | Transgenic rodents and rodent cell lines expressing hiv co-receptors |
| EP1147209A2 (de) | 1999-02-03 | 2001-10-24 | The Children's Medical Center Corporation | Genreparatur durch induzierte doppelsträngige dna-schneidung an einer chromosomalen targetstelle |
| CA2394850C (en) * | 1999-12-06 | 2012-02-07 | Sangamo Biosciences, Inc. | Methods of using randomized libraries of zinc finger proteins for the identification of gene function |
| US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20050144655A1 (en) * | 2000-10-31 | 2005-06-30 | Economides Aris N. | Methods of modifying eukaryotic cells |
| US6596541B2 (en) * | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| CA2474486C (en) | 2002-01-23 | 2013-05-14 | The University Of Utah Research Foundation | Targeted chromosomal mutagenesis using zinc finger nucleases |
| US20030232410A1 (en) | 2002-03-21 | 2003-12-18 | Monika Liljedahl | Methods and compositions for using zinc finger endonucleases to enhance homologous recombination |
| WO2004037977A2 (en) | 2002-09-05 | 2004-05-06 | California Institute Of Thechnology | Use of chimeric nucleases to stimulate gene targeting |
| US20030175968A1 (en) | 2002-10-30 | 2003-09-18 | Golic Kent G. | Gene targeting method |
| EP1587545A2 (de) * | 2003-01-13 | 2005-10-26 | Mahendra S. Rao | Anhaltende expression von molekülkandidaten in proliferierenden stamm- und vorläuferzellen zur abgabe von therapeutischen produkten |
| KR20060039019A (ko) | 2003-08-08 | 2006-05-04 | 상가모 바이오사이언스 인코포레이티드 | 표적화된 절단과 재조합을 위한 방법 및 그 조성물 |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
| KR20070060115A (ko) | 2004-09-16 | 2007-06-12 | 상가모 바이오사이언스 인코포레이티드 | 단백질 생산을 위한 조성물 및 방법 |
| AU2005295269B2 (en) | 2004-10-19 | 2010-05-13 | Regeneron Pharmaceuticals, Inc. | Method for generating an animal homozygous for a genetic modification |
| FR2879622B1 (fr) | 2004-12-17 | 2008-02-01 | Agronomique Inst Nat Rech | Procede in vitro de production d'ovocytes ou d'oeufs presentant une modification genomique ciblee |
| US10022457B2 (en) | 2005-08-05 | 2018-07-17 | Gholam A. Peyman | Methods to regulate polarization and enhance function of cells |
| GB0615327D0 (en) | 2006-03-30 | 2006-09-13 | Univ Edinburgh | Culture medium containing kinase inhibitors and uses thereof |
| CA2638774C (en) | 2006-03-31 | 2015-11-24 | Medarex, Inc. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
| US7771967B2 (en) | 2006-12-22 | 2010-08-10 | The J. David Gladstone Institutes | Nucleic acid encoding apolipoprotein E-I3 |
| US10155038B2 (en) | 2007-02-02 | 2018-12-18 | Yale University | Cells prepared by transient transfection and methods of use thereof |
| EP2137310B1 (de) | 2007-04-26 | 2010-11-24 | Sangamo BioSciences, Inc. | Gezielte integration in die ppp1r12c-position |
| ES2664218T3 (es) | 2007-06-01 | 2018-04-18 | Open Monoclonal Technology, Inc | Composiciones y procedimientos de inhibición de genes de inmunoglobulinas endógenas y de producción de anticuerpos idiotípicos humanos transgénicos |
| WO2010021692A1 (en) | 2008-08-22 | 2010-02-25 | Sangamo Biosciences, Inc. | Methods and compositions for targeted single-stranded cleavage and targeted integration |
| US20100076057A1 (en) | 2008-09-23 | 2010-03-25 | Northwestern University | TARGET DNA INTERFERENCE WITH crRNA |
| EP2180058A1 (de) | 2008-10-23 | 2010-04-28 | Cellectis | Meganuklease-Rekombinationssystem |
| WO2010065123A1 (en) | 2008-12-04 | 2010-06-10 | Sangamo Biosciences, Inc. | Genome editing in rats using zinc-finger nucleases |
| US20110239315A1 (en) | 2009-01-12 | 2011-09-29 | Ulla Bonas | Modular dna-binding domains and methods of use |
| EP2421980A2 (de) | 2009-04-23 | 2012-02-29 | Transposagen Biopharmaceuticals, Inc. | Gentechnisch veränderte rattenmodelle für krebs |
| US8772008B2 (en) | 2009-05-18 | 2014-07-08 | Sangamo Biosciences, Inc. | Methods and compositions for increasing nuclease activity |
| EP2456876A2 (de) | 2009-07-24 | 2012-05-30 | Transposagen Biopharmaceuticals, Inc. | Genetisch modifizierte rattenmodelle für zytokin-zytokin-signalwege |
| WO2011051390A1 (en) * | 2009-10-28 | 2011-05-05 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Homologous recombination in the oocyte |
| PT3147362T (pt) | 2009-10-29 | 2019-04-02 | Regeneron Pharma | Alelos multifuncionais |
| WO2011053957A2 (en) | 2009-11-02 | 2011-05-05 | Gen9, Inc. | Compositions and methods for the regulation of multiple genes of interest in a cell |
| JP5807862B2 (ja) | 2009-12-01 | 2015-11-10 | 国立研究開発法人国立がん研究センター | ラット胚性幹細胞を用いたキメララットの作製法 |
| DK2816112T3 (en) | 2009-12-10 | 2018-11-19 | Univ Minnesota | TAL effector-mediated DNA modification |
| CA2951341A1 (en) | 2009-12-21 | 2011-06-30 | Keygene N.V. | Improved techniques for transfecting protoplasts |
| KR101951489B1 (ko) | 2010-01-22 | 2019-04-22 | 다우 아그로사이언시즈 엘엘씨 | 유전적으로 변형된 유기체에서 도입유전자의 절제 |
| WO2011100058A1 (en) * | 2010-02-09 | 2011-08-18 | Sangamo Biosciences, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
| WO2011146121A1 (en) | 2010-05-17 | 2011-11-24 | Sangamo Biosciences, Inc. | Novel dna-binding proteins and uses thereof |
| GB201009732D0 (en) | 2010-06-10 | 2010-07-21 | Gene Bridges Gmbh | Direct cloning |
| WO2011156723A1 (en) | 2010-06-11 | 2011-12-15 | Regeneron Pharmaceuticals, Inc. | Production of fertile xy female animals from xy es cells |
| WO2012012667A2 (en) | 2010-07-21 | 2012-01-26 | Sangamo Biosciences, Inc. | Methods and compositions for modification of a hla locus |
| WO2012018726A1 (en) * | 2010-08-02 | 2012-02-09 | Cellectis Sa | Method for increasing double-strand break-induced gene targeting |
| WO2012129198A1 (en) | 2011-03-23 | 2012-09-27 | Transposagen Biopharmaceuticals, Inc. | Genetically modified rat models for obesity and diabetes |
| EP2718446A2 (de) | 2011-06-07 | 2014-04-16 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Verbesserte rekombinationseffizienz durch hemmung der nhej-dna-reparatur |
| KR101964776B1 (ko) | 2011-10-28 | 2019-04-04 | 리제너론 파아마슈티컬스, 인크. | 유전자 변형된 ｔ 세포 수용체 마우스 |
| US9637739B2 (en) | 2012-03-20 | 2017-05-02 | Vilnius University | RNA-directed DNA cleavage by the Cas9-crRNA complex |
| WO2013141680A1 (en) | 2012-03-20 | 2013-09-26 | Vilnius University | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX |
| IN2014DN09261A (de) | 2012-04-25 | 2015-07-10 | Regeneron Pharma | |
| KR102116153B1 (ko) | 2012-05-07 | 2020-05-27 | 상가모 테라퓨틱스, 인코포레이티드 | 도입유전자의 뉴클레아제-매개 표적화된 통합을 위한 방법 및 조성물 |
| SG10201809817UA (en) | 2012-05-25 | 2018-12-28 | Univ California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
| CN104540382A (zh) | 2012-06-12 | 2015-04-22 | 弗·哈夫曼-拉罗切有限公司 | 用于产生条件性敲除等位基因的方法和组合物 |
| PT3494997T (pt) | 2012-07-25 | 2019-12-05 | Massachusetts Inst Technology | Proteínas de ligação a adn indutíveis e ferramentas de perturbação do genoma e aplicações destas |
| CN110643600A (zh) | 2012-10-23 | 2020-01-03 | 基因工具股份有限公司 | 用于切割靶dna的系统及其用途 |
| CA2977152C (en) | 2012-12-06 | 2019-04-09 | Sigma-Aldrich Co. Llc | Crispr-based genome modification and regulation |
| WO2014093479A1 (en) | 2012-12-11 | 2014-06-19 | Montana State University | Crispr (clustered regularly interspaced short palindromic repeats) rna-guided control of gene regulation |
| EP3434776A1 (de) | 2012-12-12 | 2019-01-30 | The Broad Institute, Inc. | Verfahren, modelle, systeme und vorrichtungen zur identifikation von zielsequenzen für cas-enzyme oder crispr-cas-systeme für zielsequenzen und förderresultate davon |
| US20140310830A1 (en) | 2012-12-12 | 2014-10-16 | Feng Zhang | CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes |
| DK2921557T3 (en) | 2012-12-12 | 2016-11-07 | Broad Inst Inc | Design of systems, methods and optimized sequence manipulation guide compositions |
| DK3327127T3 (da) | 2012-12-12 | 2021-06-28 | Broad Inst Inc | Fremføring, modificering og optimering af systemer, fremgangsmåder og sammensætninger til sekvensmanipulation og terapeutiske anvendelser |
| IL300461A (en) | 2012-12-12 | 2023-04-01 | Harvard College | Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation |
| WO2014093701A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof |
| US8993233B2 (en) | 2012-12-12 | 2015-03-31 | The Broad Institute Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| EP4286403A3 (de) | 2012-12-12 | 2024-02-14 | The Broad Institute Inc. | Systeme, verfahren und zusammensetzungen mit crispr-cas-komponenten zur sequenzmanipulation |
| PT2771468E (pt) | 2012-12-12 | 2015-06-02 | Harvard College | Engenharia de sistemas, métodos e composições-guia otimizadas para manipulação de sequências |
| RU2699523C2 (ru) | 2012-12-17 | 2019-09-05 | Президент Энд Фэллоуз Оф Харвард Коллидж | Рнк-направляемая инженерия генома человека |
| JP6583918B2 (ja) | 2012-12-27 | 2019-10-02 | キージーン ナムローゼ フェンノートシャップ | 植物における遺伝連鎖を解消するための方法 |
| WO2014127287A1 (en) | 2013-02-14 | 2014-08-21 | Massachusetts Institute Of Technology | Method for in vivo tergated mutagenesis |
| EP3561050B1 (de) | 2013-02-20 | 2021-12-08 | Regeneron Pharmaceuticals, Inc. | Genetische modifikation von ratten |
| CA2901676C (en) | 2013-02-25 | 2023-08-22 | Sangamo Biosciences, Inc. | Methods and compositions for enhancing nuclease-mediated gene disruption |
| WO2014131833A1 (en) | 2013-02-27 | 2014-09-04 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) | Gene editing in the oocyte by cas9 nucleases |
| WO2014143381A1 (en) | 2013-03-09 | 2014-09-18 | Agilent Technologies, Inc. | Methods of in vivo engineering of large sequences using multiple crispr/cas selections of recombineering events |
| ES2901396T3 (es) | 2013-03-14 | 2022-03-22 | Caribou Biosciences Inc | Composiciones y métodos de ácidos nucleicos dirigidos a ácido nucleico |
| US20140349400A1 (en) | 2013-03-15 | 2014-11-27 | Massachusetts Institute Of Technology | Programmable Modification of DNA |
| US9234213B2 (en) | 2013-03-15 | 2016-01-12 | System Biosciences, Llc | Compositions and methods directed to CRISPR/Cas genomic engineering systems |
| US20140273230A1 (en) | 2013-03-15 | 2014-09-18 | Sigma-Aldrich Co., Llc | Crispr-based genome modification and regulation |
| HK1218232A1 (zh) | 2013-03-21 | 2017-02-10 | 桑格摩生物科学股份有限公司 | 使用工程化鋅指蛋白核酸酶靶向斷裂t細胞受體基因 |
| EP2981617B1 (de) | 2013-04-04 | 2023-07-05 | President and Fellows of Harvard College | Therapeutische verwendungen einer genomänderung mit crispr-/cas-systemen |
| US20160040155A1 (en) | 2013-04-16 | 2016-02-11 | University Of Washington Through Its Center For Commercialization | Activating an alternative pathway for homology-directed repair to stimulate targeted gene correction and genome engineering |
| SI2986729T1 (sl) | 2013-04-16 | 2019-02-28 | Regeneron Pharmaceuticals, Inc. | Ciljana sprememba genoma podgane |
| WO2014172470A2 (en) | 2013-04-16 | 2014-10-23 | Whitehead Institute For Biomedical Research | Methods of mutating, modifying or modulating nucleic acid in a cell or nonhuman mammal |
| EP2796558A1 (de) | 2013-04-23 | 2014-10-29 | Rheinische Friedrich-Wilhelms-Universität Bonn | Verbessertes Gen-Targeting und Nucleinsäureträgermoleküle, insbesondere zur Verwendung bei Pflanzen |
| US10563225B2 (en) | 2013-07-26 | 2020-02-18 | President And Fellows Of Harvard College | Genome engineering |
| KR102170502B1 (ko) | 2013-12-11 | 2020-10-28 | 리제너론 파마슈티칼스 인코포레이티드 | 게놈의 표적화된 변형을 위한 방법 및 조성물 |
| JP6688231B2 (ja) | 2014-06-06 | 2020-04-28 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 標的遺伝子座を修飾するための方法及び組成物 |
| SG10201911411YA (en) | 2014-06-26 | 2020-02-27 | Regeneron Pharma | Methods and compositions for targeted genetic modifications and methods of use |
| US10738278B2 (en) | 2014-07-15 | 2020-08-11 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
| NZ732895A (en) | 2014-12-19 | 2022-05-27 | Regeneron Pharma | Methods and compositions for targeted genetic modification through single-step multiple targeting |
-
2013
- 2013-04-25 IN IN9261DEN2014 patent/IN2014DN09261A/en unknown
- 2013-04-25 EP EP13720718.9A patent/EP2847335B1/de active Active
- 2013-04-25 US US13/870,280 patent/US9834786B2/en active Active
- 2013-04-25 CN CN201380030738.6A patent/CN104364380B/zh active Active
- 2013-04-25 MX MX2014012994A patent/MX362523B/es active IP Right Grant
- 2013-04-25 PL PL13720718T patent/PL2847335T3/pl unknown
- 2013-04-25 RU RU2014145942A patent/RU2645475C2/ru active
- 2013-04-25 CA CA2869016A patent/CA2869016C/en active Active
- 2013-04-25 JP JP2015509128A patent/JP6275120B2/ja active Active
- 2013-04-25 WO PCT/US2013/038165 patent/WO2013163394A1/en not_active Ceased
- 2013-04-25 KR KR1020147030262A patent/KR101904508B1/ko active Active
- 2013-04-25 CN CN201811024942.8A patent/CN109536526B/zh active Active
- 2013-04-25 DK DK13720718.9T patent/DK2847335T3/en active
- 2013-04-25 PT PT137207189T patent/PT2847335T/pt unknown
- 2013-04-25 AU AU2013251558A patent/AU2013251558B2/en active Active
- 2013-04-25 SG SG11201406547YA patent/SG11201406547YA/en unknown
- 2013-04-25 SG SG10201702445TA patent/SG10201702445TA/en unknown
- 2013-04-25 BR BR112014026294-2A patent/BR112014026294B1/pt active IP Right Grant
- 2013-04-25 ES ES13720718.9T patent/ES2683071T3/es active Active
-
2014
- 2014-09-30 IL IL234905A patent/IL234905B/en active IP Right Grant
-
2017
- 2017-10-24 US US15/792,112 patent/US10301646B2/en active Active
-
2018
- 2018-08-06 CY CY20181100810T patent/CY1120572T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN09261A (de) | ||
| EP4321623A3 (de) | Verfahren und zusammensetzungen zum genom-editieren von sich nichtteilenden zellen | |
| MY183741A (en) | Methods and compositions for increasing efficiency of targeted gene modification using oligonucleotide-mediated gene repair | |
| EP3617309A3 (de) | Crispr-basierte genommodifizierung und -regulierung | |
| PH12012501491B1 (en) | Targeted genomic alteration | |
| CA2906970C (en) | Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases | |
| EP3441468A3 (de) | Freisetzungsverfahren und zusammensetzungen für nukleasevermitteltes genomengineering | |
| EP4357452A3 (de) | Verfahren und zusammensetzungen zur erhöhung der effizienz gezielter genmodifizierung mittels oligonukleotidvermittelter genreparatur | |
| EP4286517A3 (de) | Therapeutische verwendungen einer genomänderung mit crispr-/cas-systemen | |
| WO2013188522A3 (en) | Methods and compositions for generating conditional knock-out alleles | |
| MX351043B (es) | Metodos para modificacion genomica. | |
| EP3057432A4 (de) | Verfahren und zusammensetzungen für nukleasevermitteltes genom-engineering in hämotopoietischen stammzellen | |
| EP3313991A4 (de) | Modifizierter faktor ix und zusammensetzungen, verfahren und verwendungen für gentransfer zu zellen, organen und gewebe | |
| WO2014033644A3 (en) | Methods of nuclease-based genetic engineering | |
| WO2015073683A3 (en) | Nuclease-mediated regulation of gene expression | |
| EP3698631A3 (de) | Verfahren zur abgabe von oligonukleotiden an immunzellen | |
| WO2012177810A3 (en) | Improved electric power supply and related methods | |
| EP4234703A3 (de) | Genom-engineering | |
| MX364662B (es) | Óptimos loci de maíz. | |
| MX2015014487A (es) | Modificación dirigida del genoma de rata. | |
| SG10201809901SA (en) | Generating Pluripotent Cells De Novo | |
| NZ705742A (en) | Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks | |
| IN2015DN01480A (de) | ||
| IN2014MN00992A (de) | ||
| WO2011154927A3 (en) | Direct cloning |